Cargando…
Substrate Reduction Therapy for Krabbe Disease: Exploring the Repurposing of the Antibiotic D-Cycloserine
Krabbe disease is a lysosomal storage disease that is caused by a deficiency in galactosylceramidase. Infantile onset disease is the most common presentation, which includes progressive neurological deterioration with corresponding demyelination, development of globoid cells, astrocyte gliosis, etc....
Autores principales: | LeVine, Steven M., Tsau, Sheila |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804370/ https://www.ncbi.nlm.nih.gov/pubmed/35118033 http://dx.doi.org/10.3389/fped.2021.807973 |
Ejemplares similares
-
Exploring Whether Iron Sequestration within the CNS of Patients with Alzheimer’s Disease Causes a Functional Iron Deficiency That Advances Neurodegeneration
por: LeVine, Steven M., et al.
Publicado: (2023) -
National U.S. Patient and Transplant Data for Krabbe Disease
por: Ghabash, Gabrielle, et al.
Publicado: (2021) -
Substrate reduction therapy for Krabbe disease and metachromatic leukodystrophy using a novel ceramide galactosyltransferase inhibitor
por: Babcock, Michael C., et al.
Publicado: (2021) -
Aspirin and multiple sclerosis
por: Tsau, Sheila, et al.
Publicado: (2015) -
Inhibition of D-Ala:D-Ala ligase through a phosphorylated form of the antibiotic D-cycloserine
por: Batson, Sarah, et al.
Publicado: (2017)